Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPAR-ICAS: Pemafibrate for Prevention of Atherosclerotic Cardiovascular Disease in Patients With Symptomatic Intracranial Artery Stenosis
NCT07562178Recruiting
- Sponsor
- Tokyo Women's Medical University
- Start
- May 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of pemafibrate in Intracranial arterial stenosis (ICAS) (2 arms), sponsored by Tokyo Women's Medical University. Primary endpoint: Progression in intracranial arterial stenosis on CTA at 12 months. Started May 2026; status: recruiting.
02
Drugs
pemafibrate
03
Conditions
Intracranial arterial stenosis (ICAS)
Beyond the preview
Go deeper on NCT07562178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07562178.